Steroid hormone receptors and antineoplastic chemotherapy in human breast cancer

Journal of Experimental and Clinical Cancer Research

Volumn 16, Issue 1, 1997, Pages 95-103

  Gorlich M ^a   Jandrig, B ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

antineoplastic chemotherapy; estrogen receptor; human breast cancer; progesterone receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOHEXIMIDE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MEDROXYPROGESTERONE ACETATE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PROGESTERONE RECEPTOR; RETINOID; TAMOXIFEN; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; FEMALE; HUMAN; PRIORITY JOURNAL;

EID: 0030966720     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Perren T.J.: Adjuvant therapy for operable breast cancer; more answers, new questions. Brt. J. Cancer 71: 1142-1144, 1995.
2. Morris I.D., Stephen T.M.: In vitro and in vivo interactions of methotrexate and other antimetabolites with the oestrogen high affinity receptors of the rat uterus. Br. J Cancer 47: 433-437, 1983.
3. Yang K.P., Samaan N.A.: Reduction of estrogen receptor concentration in MCF-7 human breast carcinoma cells following exposure to chemotherapeutic drugs. Cancer Res. 43: 3534-3538, 1983.
4. Pavlik E.J., Nelson K., Gallion H. et al.: The effects of acute anticancer agents on the capacity for subsequent hormonal responses in the mouse uterus. J. Steroid Biochem. 25: 231-237, 1986.
5. Maehara Y., Emi Y., Sakaguchi Y. et al.: Estrogen-receptor-negative breast cancer tissue is chemosensitive in vitro compared with estrogen-receptor-positive tissue. Eur. Surg. Res. 22: 50-56, 1990.
6. Padmannan N., Howell A., Rubens R.D.: Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet 2: 411-414, 1986.
7. Valagussa P., Bonadonna G.: Mechanism of action of adjuvant chemotherapy in early breast cancer. Letter to the editor. Lancet 2: 1035-1036, 1986.
8. Goldhirsch A., Gelber R.D., Castiglione M.: The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann. Oncol. 1: 183-188, 1990.
9. Fisher B., Sherman B., Rockette H., Redmond C., Margolese R., Fisher E.R.: L-Phenylalanin mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: Lack of association of disease-free survival with depression of ovarian function. Cancer 44: 847-857, 1979.
10. Bhatavdekar J.M., Shah N.G., Patel D.D., et al.: Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen. Neoplasma 39: 123-127, 1992.
11. Bianco A.R., Placido S.D., Pagliarulo C., et al.: Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer. Chemioterapia 4: 252-255, 1985.
12. Hilf R., Feldstein M.L., Savlov E.D., Gibson S.L., Seneca B.: The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer 46: 2797-2800, 1980.
13. Rosenbaum C., Marsland T.A., Stolbach L.L., Raam S., Cohen J.L.: Estrogen receptor status and response to chemotherapy in advanced breast cancer: The Tufts-Shattuck-Pondville experience. Cancer 46: 2919-2921, 1980.
14. Jonat W., Maass H., Stolzenbach G., Trams G.: Estrogen receptor status and response to polychemotherapy in advanced breast cancer. Cancer 46: 2809-2813, 1980.
15. Samal B.A., Brooks S.C., Cunnings G., et al.: Estrogen receptors and responsiveness of advanced breast cancer to chemotherapy. Cancer 46: 2925-2927, 1980.
16. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guys Hospital, London: Adjuvant ovarian ablation versus CMF chemotherapy in premeonpausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 341: 1293-1298, 1994.
17. Fisher B., Redmond C.K., Wickerham D.L., Rockette H.E., Brown A., and other NSABP investigators: Relation of estrogen and/or progesterone receptor content of breast cancer to patients outcome following adjuvant chemotherapy. Breast Cancer Res. Treatm. 3: 355-364, 1983.
18. Code D.K., Sears M.E., Olson K.B.: Relationship of quantitative estrogen-receptor level and clinical response to cytotoxic chemotherapy in advanced breast cancer. An extramural analysis. Cancer 54: 1554-1561, 1984.
19. Petru E., Beck K., Schunemann H., Schmahl D.: Relevance of the hormone receptor content of primary tumors in patients with advanced breast cancer undergoing cytotoxic chemotherapy. Wiener Med. Wschr. 141: 133-135, 1991.
20. Houston S.J., Richards M.A., Bentley A.E., Smith P., Rubens R.D.: The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer. Eur. J. Cancer 2A: 1513-1518, 1993.
21. Bonadonna G., Di Fronzo G., Tancini G., et al.: Relationship between estrogen receptors and CMF adjuvant therapy. Recent Results in Cancer Res. 91: 205-209, 1984.
22. Vollenweider-Zerargui L., Barrelet L., Wong Y., Lemarchand-Beraud T., Gomez F.: The predictive value of estrogen and progesterone receptors' concentrations on the clinical bevavior of breast cancer in women. Cancer 57: 1171-1180, 1986.
23. Sertoli M.R., Scarsi P.G., Rosso R.: Rationale for combining chemotherapy and hormonal therapy in breast cancer. J. Steroid Biochem. 23: 1097-1103, 1985.
24. Boccardo F., Rubagotti D., Amoroso D., et al. and other participants in the GROCTA: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast cancer adjuvant chemo-hormone therapy cooperative group) trial. Eur. J. Cancer 28: 673-680, 1992
25. Conte P.F., Fraschini G., Alama A., et al.: Chemotherapy following estrogen-induced expansion of the growth fraction of human breast cancer. Cancer Res. 45: 5926-5930 (1985).
26. Paridaens R., Heuson J.C., Julien J.P., et al. and the EORTC Breast Cancer Cooperative Group: Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: Preliminary results of a double-blind randomized study of the EORTC Breast Cancer Cooperative Group. J. Steroid Biochem. Molec. Biol. 37: 1109-1113, 1990.
27. Sutherland R.L., Green M.D., Hall R.E., Reddel R.R., Taylor: I.W.: Tamoxifen induces accumulation of MCF-7 human mammary carcinoma cells in th Go/1 phase of the cell cycle. Eur. J. Cancer Clin. Oncol. 19: 615-621, 1983.
28. Osborne C.K., Kitten L., Artega C.L.: Antagonism of chemo-therapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J. Clin. Oncol. 7: 710-717, 1989.
29. Fisher B., Redmond C., Brown A., et al. and other NSABP investigators: Adjuvant chemotherapy with and without tamoxifen: Five-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J. Clin. Oncol. 4: 459-471, 1986.
30. Fisher B., Redmond C., Legault-Poisson S., et al.: Post-operative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J. Clin. Oncol. 8: 1005-1018, 1990.
31. Hawkins R.A., Tesdale A.L., Anderson E.D.C., Levack P.A., Chetty U., Forrest A.P.M.: Does the oestrogen receptor concentration of a breast cancer change during systemic therapy? Br. J. Cancer 61: 877-880, 1990.
32. Daidone M.G., Silvestrini R., Luisi A., et al.: Changes in biological markers after primary chemotherapy for breast cancers. Int. J. Cancer 61: 301-305, 1995.
33. Teixeira C., Reed J.C., Pratt M.A.C.: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 55: 3902-3907, 1995.
34. Tormey D.C., Gray R., Abeloff M.D., et al.: Adjuvant therapy with a doxorubicin regimen and long-term-tamoxifen in premenopausal breast cancer patients: An eastern cooperative oncology group trial. J. Clin. Oncol. 10: 1848-1856, 1992.
35. Gasparini G., Barbareschi M., Doglioni C., et al.: Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res. 1: 189-198, 1995.
36. Coldham, N.G., Patel K., Braunsberg H.: Hormone and cytotoxic drug responsiveness of cultured human breast cancer cells resistant to specific hormones. Int. J. Cancer 45: 712-718, 1990.
37. Lönn U., Lönn S., Stenkvist B.: Appearance of amplified thymidylate synthase or dihydrofolate reductase genes in stage-IV breast-cancer patients receiving endocrine treatment. Int. J. Cancer 54: 237-242, 1993.
38. Lönn. U., Lönn S., Nilsson B., Stenkvist B.: Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy. Cancer 77: 107-112, 1996.
39. Osborne C.K.: Current trial and future directions of the Southwest Oncology Group Breast Cancer Committee. Cancer 74: 1135-1138, 1994.
40. Goldhirsch A., Gelber R.D., Castiglione M., Price K.N. for the International Breast Cancer Study Group: Present and future projects of the International Breast Cancer Study Group. Cancer 74: 1139-1149, 1994.
41. Gundersen S., Kvinnsland S., Klepp O., Lund E., Hannisdal E., Host H. for the Norwegian Breast Cancer Group: Chemotherapy with and without high-dose medroxyprogesterone acetate in oestrogen-receptor negative advanced breast cancer. Eur. J. Cancer 28: 390-394, 1992.
42. Formelli F., Zaccheo T., Casacca A.M., Bellini O., di Marco A.: Effect of medroxyprogesterone acetate and doxorubicin on sublines of 13762 mammary adenocarcinomas in rats. Eur. J. Cancer Clin. Oncol. 17: 1211-1221, 1981.
43. Shaikh N.A., Owen A.M., Gilchik M.W., Braunsberg H.: Actions of medroxyprogesterone acetate on the efficacy of cytotoxic drugs: Studies with human breast cancer cells in culture. Int. J. Cancer 43: 458-463, 1989.
44. Shaikh N.A., Owen A.M., Gilchik M.W., Braunsberg H.: Adriamycin action on human breast cancer cells: Enhancement by medroxyprogesterone acetate. Int. J. Cancer 43: 733-736, 1989.
45. Rubin M., Fenig E., Rosenauer A., et al.: 9-cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res. 54: 6549-6556, 1994.
46. Abrams J.S., Moore T.D., Friedman M.: New chemotherapeutic agents for breast cancer. Cancer 74: 1164-1176, 1994.
47. Gasparini G., Pozza F., Harris A.L.: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients (Review). J. Natl. Cancer Inst. 85: 1206-1219, 1993.
48. Henderson I.C.: Adjuvant systemic therapy for early breast cancer. Cancer 74: 401-409, 1994.
49. Gotteland M., May E., May-Levin F., Contesso G., Delarue J.C. Mouriesse H.: Estrogen receptor (ER) in human breast cancer: The significance of a new prognostic factor based on both ER protein and ERmRNA contents. Cancer 74: 864-871, 1994.
50. Thorpe S.M., Christensen I.J., Rasmussen B.B., Rose C.: Short recurrence free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur. J. Cancer 29A: 971-977, 1993.
51. Gaskell D.J., Sangster K., Tesdale A.L., Carson D., Hawkins: R.A.: Change in the oestrogen receptor status of breast cancer with age-comparison of two types of assay. Br. J. Cancer 66: 610-613, 1992.
52. Walker K.J., McClelland R.A., Candlish W., Blamey R.W., Nicholson R.I.: Heterogeneity of estrogen receptor expression in normal and malignant breast tissue. Eur. J. Cancer 28: 34-37, 1992.
53. Fuqua S.A.W., Fitzgerald S.D., Allred D.C., et al.: Inhibition of estrogen receptor action by a naturally occuring variant in human breast tumors. Cancer Res. 52: 483-486, 1992.
54. Castles C.G., Klotz D.M., Fuqua S.A.W., Hill S. M.: Coexpression of wild-type and variant oestrogen receptor mRNAs in a panel of human breast cancer cells. Br. J. Cancer 71: 974-980, 1995.
55. Van Agthoven T., van Agthoven T.L.A., Dekker A., Foekens J.A., Dorssers L.C.J.: Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Molec. Endocrinol. 8: 1474-1483, 1994.
56. Pfeffer U., Fecarotta E., Vidali G.: Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res. 55: 2158-2165, 1995.
57. Nagai M.A., Marques A., Yamamoto L., Fujiyama C.T., Brentani M.M.: Estrogen and progesterone receptor mRNA levels in primary breast cancer: Association with patient survival and other clinical and tumor features. Int. J. Cancer 59: 351-356, 1994.
58. Horwitz K.B.: Hormone «resistance» in breast cancer: The role of normal and mutant steroid receptors. In: Dickson R., Lippman M., eds.: Mammary tumorigenesis and malignant progression. Kluwer Academic Publishers, Dor Carboplatin Regimen With GM-CSF Support in Non-drecht, 111-127, 1994.
59. Katzenellenbogen J.A., Coleman R.E., Hawkins R.A,. et al.: Tumor receptor imaging: Proceedings of the National Cancer Institute Workshop, review of current work, and prospective for further investigations. Clin. Cancer Res. 1: 921-932, 1995.